Technology Appraisal Virtual Committee Meeting

Committee A

Zoom

## Minutes: Confirmed

## Date and Time: Tuesday 9 June 2020 09:30 - 3.00pm

### Present:

1. Dr Jane Adam (Chair) Present for all notes
2. Dr Brian Shine (Vice Chair) Present for all notes
3. Dr Peter Baker Present for all notes
4. Mr Richard Ballerand Present for all notes
5. Dr Andrew Champion Present for all notes
6. Dr Justin Daniels Present for all notes
7. Dr Rita Faria Present for all notes
8. Dr Khalida Ismail Present for all notes
9. Professor G.J. Melendez-Torres Present for all notes
10. Mrs Becky Pennington Present for all notes
11. Ms Pamela Rees Present for all notes
12. Mr Stephen Sharp Present for all notes
13. Dr Alice Turner Present for all notes
14. Dr Mark Upton Present for all notes
15. Dr Min Ven Teo Present for all notes
16. Dr Roger Whittaker Present for all notes

**In attendance:**

* Janet Robertson, Associate Director, NICE, Present for all notes
* Thomas Feist, Project Manager, NICE, Present for all notes
* Marcia Miller, Administrator, NICE, Present for all notes
* Rufaro Kausi, Technical Adviser, NICE, Present for all notes
* Caroline Bregman, Technical Analyst, NICE, Present for all notes
* Laura Marsden, Coordinator, NICE, Present for all notes
* Jenna Dilkes, Programme Manager, NICE, Present for all notes
* Nick Lowe, Digital Services, NICE, Present for notes 1 to 4
* Oswin Jackson, Digital Services, NICE, Present for notes 1 to 4
* Dr Andrew Veitch, Clinical Expert, Gastroenterologist, Present for notes 1 to 4
* Dr Deepa Arachchillage, Clinical Expert, Consultant Haematologist, Present for notes 1 to 4
* Professor Liz Warburton, Clinical Expert, Professor of Stroke Medicine, Present for notes 1 to 4
* Diane Eaton, Patient Expert, Consultant Project Manager, Anticoagulation UK, Present for notes 1 to 4
* Jo Jerrome, Patient Expert, CEO Thrombosis UK, Present for notes 1 to 4
* Gemma Marceniuk, BMJ-TAG, Evidence Review Group, Present for notes 1 to 4
* Steve Edwards, BMJ-TAG, Evidence Review Group, Present for notes 1 to 4
* Victoria Wakefield, BMJ-TAG, Evidence Review Group, Present for notes 1 to 4

### Non-public attendees:

* Catrin Austin, Technical Analyst, Guidelines, NICE, Present for all notes
* Gita Bhutani, Committee Chair, HSC, NICE, Present for notes 1 to 4
* Rebecca Boffa, Senior HTA Analyst, BMJ, Present for all notes
* Sarah Boyce, Technical Analyst, Public Health, NICE, Present for all notes
* Lise Elliot, Programme Manager, Public Health, NICE, Present for all notes
* Brad Groves, Managed Access Associate Director, NICE, Present for all notes
* Claire Hawksworth, Managed Access Technical Analyst, NICE, Present for all notes
* Masuma Jaffer, Technical Analyst, TA, NICE, Present for all notes
* James Jagroo, Senior Technical Analyst, Public Health, NICE, Present for notes 1 to 4
* Heidi Livingstone, Public Involvement adviser, NICE, Present for notes 1 to 4
* Rosalee Mason, Corporate Office Coordinator, NICE, Present for notes 1 to 4
* George Millington, Assistant Technical Analyst, TA, NICE, Present for all notes
* Catherine Pank, Corporate Office Coordinator, NICE, Present for notes 1 to 4
* Maria Pitan, Corporate Office Project Manager, NICE, Present for notes 1 to 4
* Ria Skelton, Appraisals Editor, NICE, Present for all notes
* Hannah Stockton, Technical Analyst, Public Health, NICE, Present for all notes
* Adam Storrow, Resource Impact Team, NICE, Present for all notes 1 to 4
* Eileen Taylor, Technical Analyst, HSC, NICE, Present for notes 1 to 4

## Notes

### Any other Business

1. None.

### Minutes from the last meeting

1. The committee approved the minutes of the committee meeting held on Tuesday 12 May 2020.

## Appraisal of andexanet alfa for reversing anticoagulation [ID1101]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Portola Pharmaceuticals.
2. The Chair asked all committee members, experts, ERG/AG representatives and NICE staff present to declare any relevant interests  
   1. Professor Liz Warburton declared direct non-financial interest as she participated in the OPTIMAS trial, funded by BHF and Stroke Association. She has previously been local PI on various RCTs and in 2016 received a grant from Pfizer Pharmaceuticals via the NHS Academic Health Sciences Networks for innovation in stroke prevention in AF.
      1. It was agreed that these declarations would not prevent her from participating in this section of the meeting.
   2. Dr Deepa Arachchillage declared an indirect interest as she has given expert lectures in a meeting supported by Portola Pharmaceuticals, but had no direct contact with Portola Pharmaceuticals.
      1. It was agreed that this declaration would not prevent her from participating in this section of the meeting.
   3. No further conflicts of interest were declared for this appraisal.
   4. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
   5. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.